Table 3 Adjusted difference in non-asthma drug costs per patient per year relative to control group
From: The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis
Base: No OCS exposure (Non-asthma control) | Adjusted cost differences | Lower bound CI (95%) | Upper bound CI (95%) | |
|---|---|---|---|---|
Low OCS exposure (Mild/Moderate asthma) | Female | £ 115a | £ 82 | £ 148 |
Male | £ 106a | £ 77 | £ 135 | |
Total | £ 112a | £ 80 | £ 143 | |
High OCS exposure (Severe asthma) | Female | £ 789a | £ 652 | £ 927 |
Male | £ 744a | £ 620 | £ 868 | |
Total | £ 772a | £ 641 | £ 903 |